ATLASImmunityBio (IBRX) Q3 2026 earnings results
ImmunityBio (IBRX) reported EPS of -$0.09 against an analyst estimate of -$0.08: a miss of $0.01 (12.5%). The quarter ended Sep 30, 2026; the company reported on Tuesday, November 10, 2026.
Status: Confirmed · 06:00 ET, Nov 10 · Source: EODHD (calendar and fundamentals, cross-checked)
Get an email before and after ImmunityBio reports, free with your ATLAS account
Earnings alerts are a free benefit of your ATLAS account. The company goes to your watchlist and we email you when it reports. Google signup is one click.
Create free accountIBRX Q3 2026 results at a glance
| EPS reported | -$0.09 |
|---|---|
| EPS estimate | -$0.08 |
| Surprise | Miss · -$0.01 (-12.5%) |
| Quarter ended | Sep 30, 2026 |
| Reported | Nov 10, 2026 |
| Status | Confirmed · 06:00 ET, Nov 10 |
EPS is as supplied by EODHD, in US dollars per share; whether it is adjusted or GAAP follows that source. This is ImmunityBio’s Q3 2026, a calendar-year company.
ImmunityBio EPS surprise history: last 5 quarters
ImmunityBio beat the EPS estimate in 2 of its last 5 reports, with an average surprise of -26.4%.
| Report date | EPS est. | EPS actual | Surprise | Result | Move* |
|---|---|---|---|---|---|
| Nov 10, 2026 | -$0.08 | -$0.09 | -12.5% | Miss | – |
| Aug 4, 2026 | -$0.08 | -$0.22 | -175.0% | Miss | +1.4% |
| May 7, 2026 | -$0.07 | -$0.08 | -14.3% | Miss | +1.6% |
| Feb 23, 2026 | -$0.10 | -$0.06 | +40.0% | Beat | +32.8% |
| Nov 5, 2025 | -$0.10 | -$0.07 | +30.0% | Beat | +1.9% |
*Move: change in the closing price from the last close before the report day to the close the day after it. It is filled in a few trading days after each report.
IBRX stock reaction to the report
IBRX moved -6.19% in the first session that reflects the report (close of Nov 9, 2026 $7.11 to close of Nov 11, 2026 $6.67). Since the report: -14.63% (latest close $6.07 on Nov 12, 2026, against $7.11 before the reaction).
Next IBRX earnings report
ImmunityBio has not announced its next earnings date yet. This page shows a date only once it is confirmed. See the IBRX earnings calendar.
ATLAS fair value and signal for IBRX
| Last price | $6.07 (-9.0%) |
|---|---|
| Chance of a higher close in 1 month | 44% (normal range $4.82–$7.01) |
These are model outputs from the same valuation and calibrated model as the ImmunityBio stock page. They describe an ordinary period and are not a forecast of any particular outcome.
ImmunityBio Q3 2026 earnings: frequently asked questions
Did ImmunityBio beat earnings estimates for Q3 2026?
ImmunityBio reported EPS of -$0.09 against an analyst estimate of -$0.08: a miss of $0.01 (12.5%).
When did ImmunityBio report Q3 2026 results?
ImmunityBio reported on Tuesday, November 10, 2026, for the quarter ended Wednesday, September 30, 2026.
How often does IBRX beat EPS estimates?
In its last 5 reports with a recorded result, ImmunityBio beat the EPS estimate 2 times; the average surprise was -26.4%. Past results do not predict the next one.
How does ATLAS confirm a result?
A result is published only after it is cross-checked: the EODHD earnings calendar and the EODHD fundamentals feed must show the same EPS for the same fiscal period, or the same value must appear in two consecutive checks. Unconfirmed figures are never published. If the figures are revised later, this page updates.
Educational information, not investment advice. Disclaimer